In its rebuttal, NTK maintained that Daiichi Sankyo has caused the company “significant losses” by preventing NTK from proceeding with the open offers. NTK said it will also seek an injunction to prevent Daiichi Sankyo from making defamatory remarks and specific actions to vindicate its reputation.
IHH Healthcare’s indirect subsidiary, Singapore-headquartered Northern TK Venture (NTK), says Daiichi Sankyo’s latest release dated May 22 contains “misleading statements” that continue to damage NTK’s interests.
In the release, the Japanese drugmaker said NTK’s claims that it interfered with the latter’s open offer are “without any merit or substance” and that the claims are “not sustainable”.
